2 minutes reading time (329 words)

Lorlatinib Approved for ALK-Positive Metastatic NSCLC

Metastatic lung cancer. Courtesy of Yale Rosen

Lorlatinib (Lorbrena®, Pfizer, Inc.) is approved as second- or third-line treatment for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

FDA approval was granted based on a non-randomized, dose-ranging and activity-estimating, multi-cohort, multicenter study (Study B7461001; NCT01970865) of 215 patients with ALK-positive metastatic NSCLC who were previously treated with one or more ALKinhibitors. Overall response rate (ORR) and intracranial ORR, according to RECIST 1.1, were measured by an independent review committee.

Lorlatinib produced an overall response rate of 48%,with 4% complete and 44% partial responses. The median duration of response was 12.5 months. The intracranial ORR in 89 patients with measurable lesions in the central nervous system according to RECIST 1.1 was 60%, with 21% complete and 38% partial responses. The median duration of response was 19.5 months.

FDA granted lorlatinib accelerated approval based on tumor response rate and duration of response.

According to Alice T. Shaw, MD, PhD, Professor of Medicine at Harvard Medical School and Director of the Center for Thoracic Cancers at Massachusetts General Hospital, "The last decade has witnessed dramatic improvements in the treatment of metastatic ALK-Positive non-small cell lung cancer due to earlier generation ALK biomarker-driven therapies. Yet almost all patients still relapse due to drug resistance, with a large proportion of patients developing new or worsening brain metastases.In a clinical study which included patients with or without brain metastases, Lorbrena demonstrated clinical activity in patients with metastatic ALK-positivenon-small cell lung cancer who had failed other ALK biomarker-driven therapies."

For More Information

Clinicaltrials.gov (2018). A study of PF-06463922 an ALK/ROS1 inhibitor in patients with advanced non small cell lung cancer with specific molecular alterations. NLM identifier: NCT01970865.

Related Posts

By accepting you will be accessing a service provided by a third-party external to https://oncdata.com/


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.